Protagenic Therapeutics, Inc. (NASDAQ:PTIX) Short Interest Update

Protagenic Therapeutics, Inc. (NASDAQ:PTIX) was the recipient of a significant decline in short interest during the month of March. As of March 31st, there was short interest totalling 70,400 shares, a decline of 62.1% from the March 15th total of 185,700 shares. Based on an average daily trading volume, of 5,130,000 shares, the days-to-cover ratio is currently 0.0 days. Approximately 1.1% of the shares of the stock are sold short.

Protagenic Therapeutics Stock Performance

Shares of PTIX stock traded down $0.01 on Wednesday, hitting $0.27. The company had a trading volume of 46,899 shares, compared to its average volume of 1,465,868. Protagenic Therapeutics has a twelve month low of $0.18 and a twelve month high of $1.87. The stock’s 50-day moving average is $0.28 and its two-hundred day moving average is $0.46. The firm has a market cap of $2.05 million, a P/E ratio of -0.21 and a beta of 0.34.

Protagenic Therapeutics (NASDAQ:PTIX) last posted its earnings results on Monday, March 31st. The company reported ($0.24) earnings per share (EPS) for the quarter.

Protagenic Therapeutics Company Profile

Protagenic Therapeutics, Inc, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses.